Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
73.4M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
42.3M
-
Shares change
-
+14.3M
-
Total reported value, excl. options
-
$170M
-
Value change
-
+$59M
-
Number of buys
-
52
-
Number of sells
-
-32
-
Price
-
$4.02
Significant Holders of Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) as of Q2 2025
108 filings reported holding LXEO - Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2025.
Lexeo Therapeutics, Inc. - Common Stock, $0.0001 par value per share (LXEO) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.3M shares
of 73.4M outstanding shares and own 57.56% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (4.42M shares), Balyasny Asset Management L.P. (4.01M shares), JANUS HENDERSON GROUP PLC (3.68M shares), CITADEL ADVISORS LLC (3.61M shares), Affinity Asset Advisors, LLC (3.59M shares), Vestal Point Capital, LP (3.23M shares), MILLENNIUM MANAGEMENT LLC (2.84M shares), Woodline Partners LP (2.57M shares), VANGUARD GROUP INC (2M shares), and BlackRock, Inc. (1.83M shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.